Cerveau Technologies Inc.

35 articles about Cerveau Technologies Inc.

• Cerveau Technologies Inc. and Prothena Sign Agreement to Provide Novel Tau Imaging Biomarker for Research and Development of Investigational Therapeutics for Neurodegenerative Diseases

  1/10/2023

  Cerveau Technologies, Inc. today announced a research collaboration agreement with Othair Prothena Limited, a subsidiary of Prothena Corporation plc (Prothena), which will enable Prothena to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain.

• Cerveau Technologies Inc. and LEXEO Therapeutics, Inc.- Sign Agreement to Provide Novel Tau Imaging Biomarker for Disease Modifier Research

  11/7/2022

  Cerveau Technologies, Inc. announced a license agreement with LEXEO Therapeutics, Inc., which will enable LEXEO to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography scans to assess the status and progression of neurofibrillary tangles in the brain.

• Cerveau Technologies Inc. and Alnylam® Pharmaceuticals Sign Agreement to Provide Novel Tau Imaging Biomarker for Disease Modifier Research

  9/1/2022

  Cerveau Technologies, Inc. announced a research collaboration agreement with Alnylam® Pharmaceuticals, which will enable Alnylam to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography scans to assess the status and progression of neurofibrillary tangles in the brain.

• Cerveau Technologies Inc. Signs Agreement with Roche to Provide Novel Tau Imaging Biomarker for Disease Modifier Research

  3/10/2022

  Cerveau Technologies, Inc. announced a research collaboration agreement with Roche Products Limited, on the use of Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography scans to assess the status and progression of neurofibrillary tangles in the brain.

• Cerveau Technologies, Inc. and Nihon Med-Physics Co., Ltd. Announce Manufacturing Service Agreement for [18F]MK-6240 in Japan

  2/22/2022

  Cerveau Technologies, Inc. (Cerveau) and Nihon Medi-Physics (NMP), a leading company for radiopharmaceuticals in Japan, today announced that they signed a manufacturing service agreement, in which Cerveau grants NMP the right to manufacture [18F]MK-6240, a next generation investigational Positron Emission Tomography (PET) imaging agent.

• Cerveau Technologies, Inc. Announces Collaboration with University College of London

  5/4/2020

  Cerveau Technologies Inc. today announced a research collaboration with University College London (UCL), a leading UK academic center for the production and application of imaging biomarkers for use in clinical research, that grants the institution the right to manufacture [ 18 F]MK-6240, a next generation investigational Positron Emission Tomography (PET) imaging agent. The facility has been fully qualified by Cerveau to produce t

• Cerveau Technologies, Inc. Announces Collaboration with Alector, Inc.

  3/20/2020

  Cerveau Technologies Inc. today announced a licensing agreement with Alector, in which Cerveau will provide its investigational imaging agent (MK-6240) to Alector for use in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs, made up of aggregated tau protein, are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease. A

• Cerveau Technologies, Inc. Announce Initiation of Japanese Phase I Study

  11/14/2019

  Cerveau Technologies, Inc. today announced that the first healthy volunteer was injected and scanned in the Japan Phase I study of [F18]MK-6240, an investigational imaging agent

• Cerveau Technologies Inc. Signs Research Agreement with Takeda to Provide Novel Tau Imaging Agent

  9/27/2019

  Cerveau Technologies, Inc. announced a research collaboration agreement with Takeda Pharmaceutical Company Limited (Takeda), which will enable Takeda to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain.

• Cerveau Technologies, Inc. Announces a Partnership with LuMind IDSC Foundation to Study Accumulation of Neurofibrillary Tau in Down Syndrome

  5/9/2019

  Cerveau Technologies, Inc. today announced a research collaboration with the LuMind IDSC Foundation (LuMind IDSC) involving use of Cerveau’s investigational imaging agent (MK-6240) in a multicenter clinical trial aimed at assessing accumulation of misfolded tau protein in people with Down syndrome (DS)

• Cerveau Technologies Inc. Signs Research Agreement with Eisai Inc., for Novel Tau Imaging Agent

  3/22/2019

  Cerveau Technologies, Inc. today announced a research collaboration agreement with Eisai Inc., which will enable Eisai to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain.

• Cerveau Technologies, Inc. and Institut de Radiofarmacia Aplicada de Barcelona, S.L. Announce Agreement to Manufacture Investigational Tau Ligand, [18F]MK-6240

  2/19/2019

  This week Institut de Radiofarmacia Aplicada de Barcelona, S.L., a leading producer of imaging biomarkers for use in clinical research, has signed an agreement that grants the company the right to manufacture [18F]MK-6240, a next generation investigational Positron Emission Tomography imaging agent.

• Cerveau Technologies, Inc. to Support a First Clinical Study in Asia of a Novel Biomarker of Alzheimer’s Disease

  12/13/2018

  Cerveau Technologies Inc. today announced that the Memory Aging and Cognition Centre (MACC) at the National University Health System (NUHS) in Singapore has initiated a study with an early stage imaging agent [18F]MK-6240 to be used in Positron Emission Tomography (PET) scans for assessing the level and progression of neurofibrillary tangles (NFTs) in the brain.

• Cerveau Technologies Inc. Announces Expanded Research Access to Novel Tau Imaging Agent

  8/7/2018

  This expansion has been driven by the increasing interest in [18F]MK-6240 as a developmental and investigational tool in clinical trials.

• Cerveau Technologies, Inc. Signs Research Agreement with Tokyo Metropolitan Institute of Gerontology, Japan

  5/15/2018

  Cerveau Technologies Inc. today announced an agreement with the Tokyo Metropolitan Institute of Gerontology in Japan to support multiple projects over the next several years.

• Navidea Signs Deal to Sublicense NAV4694 Worldwide Development Rights

  4/16/2018

  NAV4694 is a beta-amyloid imaging agent being evaluated as an aid in the differential diagnosis of early-onset Alzheimer’s disease

• Cerveau Technologies, Inc. Signs Research Agreement with Massachusetts General Hospital

  2/8/2018

  Cerveau Technologies Inc. today announced an agreement with Massachusetts General Hospital (MGH) to support multiple projects over the next several years.

• Cerveau Technologies, Inc. Signs Research Agreement with University of Pittsburgh

  1/17/2018

  Cerveau Technologies Inc. today announced an agreement with the University of Pittsburgh to support multiple projects over the next several years.

• Cerveau Technologies Ink R&D Deal With KU Leuven University, Belgium

  12/15/2017

  The deal will support multiple projects over the next several years.

• Cerveau Technologies Signs Research Agreement With VU Medical Center Amsterdam

  12/6/2017

  These research projects are for studies of an early stage imaging agent (MK-6240) to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain.